Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
City University of Hong Kong CityU
Member
Glycos Biomedical LtdWe are UK/US entity with a team based in Maryland and North Carolina comprising an expert team that has linked triggers to disease states including TBI and acute injuries associated with radiation, acute lung injury and infection.
We are UK/US entity with a team based in Maryland and North Carolina comprising an expert team that has linked triggers to disease states including TBI and acute injuries associated with radiation, acute lung injury and infection.
Publication Number
US-12624359-B2
Publication Date
2026-05-12
Expiration Date
Abstract
Disclosed herein is a method of identifying an L-RNA aptamer specific for a target nucleic acid. According to some embodiments of the present disclosure, the method comprises, in vitro transcribing the DNAs of the DNA library into D-RNAs, followed by identifying target-specific D-RNAs via negative and positive selections, and then producing the L-RNA aptamer based on the identified D-RNA. Also disclosed herein are two aptamers identified by the present method. According to some embodiments of the present disclosure, the two aptamers respectively comprise the nucleotide sequences of SEQ ID NOs: 1 and 2.
Core Innovation
The invention provides an L-form ribonucleic acid (L-RNA) aptamer identification approach for G-quadruplex (G4) nucleic acids, using an rG4-SELEX-like workflow. A randomized DNA library is transcribed in vitro to D-RNAs, and an iterative selection scheme is performed with negative and positive selections using tRNA-blocked streptavidin beads and biotinylated target nucleic acids.
The selected nucleic acids are then converted to cDNA and amplified by PCR, with repetition at least through four rounds. After selection, the corresponding L-RNA aptamer is chemically synthesized, and the workflow is applied to identify aptamers that specifically bind G4 nucleic acids with enantiomeric specificity.
The document discloses aptamers L-Apt.8f (SEQ ID NO:1) and L-Apt.12-6 (SEQ ID NO:2). L-Apt.8f is described as binding the APP 3′-UTR rG4, with enantiomeric specificity and functional translational repression assessed using dual-luciferase reporting and G4-mutant controls.
L-Apt.12-6 is described as binding parallel G4 targets, including the c-kit dG4/rG4, with parallel-topology selectivity supported by binding assays and reporter effects. Characterization and sequence assessment approaches are described to support aptamer binding and structural/ligand-dependent behavior.
Claims Coverage
The independent claims are directed to two L-RNA aptamers defined by their nucleotide sequences and target specificity, comprising two inventive features: an APP 3′-UTR-specific L-RNA aptamer sequence (SEQ ID NO: 1) and an L-RNA aptamer sequence (SEQ ID NO: 2) specific for a target nucleic acid having a parallel G-quadruplex structure.
App 3′-utr-specific l-rna aptamer sequence
An L-form ribonucleic acid (L-RNA) aptamer specific for the 3′-untranslated region (3′-UTR) of amyloid precursor protein (APP) messenger RNA (mRNA), comprising the nucleotide sequence of SEQ ID NO: 1.
Parallel g-quadruplex-specific l-rna aptamer sequence
An L-form ribonucleic acid (L-RNA) aptamer specific for a target nucleic acid having a parallel G-quadruplex structure, comprising the nucleotide sequence of SEQ ID NO: 2.
Overall, the claim coverage centers on L-RNA aptamers characterized by SEQ ID NO: 1 for APP 3′-UTR (rG4) specificity and by SEQ ID NO: 2 for a parallel G-quadruplex target nucleic acid.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?